Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.
about
Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with SchizophreniaDetermination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters.The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine.Simultaneous quantification of olanzapine and its metabolite N-desmethylolanzapine in human plasma by liquid chromatography tandem mass spectrometry for therapeutic drug monitoring.Metabolic drug interactions with newer antipsychotics: a comparative review.Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.Sex-specific differences in side effects of psychotropic drugs: genes or gender?Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?Interactions between antiepileptics and second-generation antipsychotics.Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Pharmacogenetics of olanzapine metabolism.The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy.Clinically significant drug interactions with atypical antipsychotics.Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis.A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients.Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia.Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis.Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients.
P2860
Q28550024-FD88413F-3584-4ADA-AC4B-B30C264C6ED9Q34761472-B8ADBD95-A16F-4D39-BD78-90E3400BE7DEQ34830210-FDAC57D3-7B30-4D66-A50C-345B9B0809FFQ35314552-220D07ED-73F0-4CA5-AC1C-88831B7C2B89Q36703845-79B38651-1FE7-4108-ABDA-CE45A2202D9EQ37157901-A3CE2516-041B-4A93-9B93-7BE85502E342Q37598900-0AF245CB-AE9E-42FF-8242-0C55B8C1BC90Q37886136-9AA3048B-65AC-412D-8256-7F1BF4C18917Q37983921-87352927-31B6-4925-8A2B-33C18681879AQ38103885-C845424E-2641-4297-9383-3A790B99A96CQ38127716-144BE9F0-6FF8-4A8E-8916-A26702552B3AQ38154910-5F1FEE8D-1479-49C7-8AED-B5C3F370F998Q38156416-B0E1E46D-1236-4B53-898E-D045CDD77A3AQ38536939-7798E4F4-5AA5-4462-9DC8-7FD93F3F46A9Q38630825-33E49D5D-775B-4A1D-B377-3C38170D073EQ38734067-CB7079D7-48AC-43A6-82D5-AA7371D650E9Q43462837-7741D1E9-9AE1-4B5D-A429-F25DC864AB7AQ45918280-C4C2BB40-05DC-4535-A360-0EBA5F7A0EC9Q49546782-3A193B8E-0086-4439-A508-6FBF5D4FBA9EQ50736144-82CBA593-37AF-4E95-B8E0-3564DF94E425
P2860
Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Therapeutic drug monitoring da ...... naturalistic clinical setting.
@ast
Therapeutic drug monitoring da ...... naturalistic clinical setting.
@en
type
label
Therapeutic drug monitoring da ...... naturalistic clinical setting.
@ast
Therapeutic drug monitoring da ...... naturalistic clinical setting.
@en
prefLabel
Therapeutic drug monitoring da ...... naturalistic clinical setting.
@ast
Therapeutic drug monitoring da ...... naturalistic clinical setting.
@en
P2093
P1476
Therapeutic drug monitoring da ...... naturalistic clinical setting.
@en
P2093
Elisabeth Skogh
Finn Bengtsson
Jöns Lundmark
Margareta Reis
Marja-Liisa Dahl
P304
P356
10.1097/00007691-200208000-00010
P577
2002-08-01T00:00:00Z